Estrogen receptors (ERs) regulate transcription by interacting with regulatory elements in target genes. However, known ER regulatory elements cannot explain the expression profiles of genes activated by estradiol (E 2 ) and selective estrogen receptor modulators (SERMs). We previously showed that the killer cell lectin-like receptor (NKG2E) gene is regulated by E 2 , tamoxifen, and raloxifene. Here we used the NKG2E gene as a model to investigate the mechanism whereby target genes are regulated by E 2 and SERMs with ER␣. The ER regulatory element in the NKG2E promoter was mapped to the ؊1825 and ؊1686 region. Full activation of the NKG2E promoter required the collaboration between a transcription factor cluster containing c-jun, heat-shock factor 2, and CCAAT/enhancer-binding protein ␤ and a unique variant estrogen response element (ERE) that has only a two nucleotide spacer between half sites. The cluster elements and the variant ERE were inactive on their own, but the regulation by E 2 and SERMs was restored when the c-jun, heat-shock factor-2, and CCAAT/enhancerbinding protein ␤ cluster was placed upstream of the variant ERE. The activation of the NKG2E gene by E 2 and selective ER modulators was associated with the recruitment of the p160 coactivators glucocorticoid receptor-interacting protein 1 and amplified in breast cancer 1 but not steroid receptor coactivator 1. These studies identified one of the most complex ER regulatory units thus far reported and demonstrate that a cluster of flanking transcription factors collaborate with ER to induce a functional ERE in the NKG2E promoter. (Endocrinology 148: 3449 -3458, 2007)
(ERE) that has only a two nucleotide spacer between half sites. The cluster elements and the variant ERE were inactive on their own, but the regulation by E 2 and SERMs was restored when the c-jun, heat-shock factor-2, and CCAAT/enhancerbinding protein ␤ cluster was placed upstream of the variant ERE. The activation of the NKG2E gene by E 2 and selective ER modulators was associated with the recruitment of the p160 coactivators glucocorticoid receptor-interacting protein 1 and amplified in breast cancer 1 but not steroid receptor coactivator 1. These studies identified one of the most complex ER regulatory units thus far reported and demonstrate that a cluster of flanking transcription factors collaborate with ER to induce a functional ERE in the NKG2E promoter. (Endocrinology 148: 3449 -3458, 2007) E STROGENS AND SELECTIVE estrogen receptor modulators (SERMs) induce physiological and clinical effects by interacting with estrogen receptors (ERs), which are members of a large family of proteins known as nuclear receptors (1, 2) . Two types of ERs have been identified, ER␣ and ER␤ (3, 4) . These receptors have different tissue distributions and biological roles. ERs act through two signaling pathways: a genomic pathway, in which ERs in the nucleus regulate gene transcription (5) , and a nongenomic pathway, in which ERs located in the plasma membrane regulate signal transduction (6) . Binding of estradiol (E 2 ) to nuclear ER induces a conformational change of the receptor that allows it to directly attach to an estrogen response element (ERE) (7) . Once the liganded ER is tethered to an ERE, distinct classes of coregulatory proteins, including p160s coactivators, mediator complex proteins, and cAMP response element-binding (CREB) protein/p300, and histone acetyltransferases are recruited in a sequential and cyclical manner that activate gene transcription (8 -11) .
ERs bind to the classical ERE as a dimer through two zinc fingers in the central DNA binding domain. The classical ERE consists of a 13-nucleotide inverted palindromic sequence separated by any three nucleotides (5Ј GGTCAnnnTGACC 3Ј). This ERE was first discovered in the Xenopus vitellogenin gene (12, 13) . Surprisingly, this exact classical ERE sequence is only found in a few human genes (14, 15) . However, ERE variants with one or two nucleotide substitutions have been found in numerous mammalian genes that are activated by ER␣ and ER␤ (16, 17) .
Although the ERE is considered to be the major response element in genes regulated by ERs, additional elements are required to regulate the full pattern of target genes and to elicit tissue-specific gene expression by E 2 and SERMs. Activator protein 1 (AP-1) and stimulatory protein 1 (Sp1) are the best characterized alternative elements present in ER target genes activated by E 2 and SERMs (18, 19) . The AP-1 element binds the transcription factors jun and fos (20, 21) , whereas Sp1 elements are GC-rich regions that bind the Sp1 family of transcription factors (22) . The alternative elements can be distinguished from an ERE in several ways. First, ER is tethered to alternative elements through protein-protein interactions rather than binding directly to DNA (23) (24) (25) . Second, whereas the ERE is typically activated by E 2 and antagonized by SERMs, the alternative elements can be activated by both E 2 and SERMs (25) (26) (27) (28) . Third, the ERE is activated by E 2 in all tissues, whereas alternative elements are activated by E 2 and SERMs in a tissue-specific manner and therefore can mediate tissue-specific effects of E 2 and SERMs (25) (26) (27) (28) .
Although the ERE and alternative elements are important mediators of the ER regulation of genes, recent microarray data from our laboratory and others (29 -31) have revealed a pattern of gene regulation by E 2 and SERMs that cannot be understood by the pharmacology of the known response elements. For example, many genes regulated by E 2 with ER␣ are distinct from those regulated by ER␤, and some genes that are regulated by tamoxifen are different from those regulated by raloxifene (30) . Because it is known that both ER␣ and ER␤ activate an ERE (32, 33) , it is likely that the genes differentially regulated by ER␣ and ER␤ contain response elements other than EREs. Furthermore, both tamoxifen and raloxifene activate AP-1 and Sp1 elements with ER␣ and ER␤ (27, 28, 34) , making it unlikely that these elements are responsible for the differential activation of genes by these drugs. Together, these findings suggest that, in addition to the ERE and known alternative elements, other types of elements exist in ER target genes that are regulated by E 2 and SERMs. Identifying novel regulatory elements in ER target genes is a critical step in the elucidation of how estrogens and SERMs induce both therapeutic and adverse effects.
One of the ER target genes that exhibited an interesting pharmacological profile in our microarrays is the killer cell lectin-like receptor (NKG2E) gene. In our studies with U2OS cells expressing ER␣, both tamoxifen and raloxifene elicited an agonist effect similar to E 2 (30) . These studies indicate that the NKG2E gene could be used as a model to better understand the mechanism whereby E 2 and SERMs activate regulatory elements in the context of a native gene rather than simple consensus elements such as AP-1 and Sp1. In the present study, we identified a complex ER regulatory element that requires the collaboration between ER␣ and multiple transcription factors. We also show that the p160 coactivators mediate the activation of the NKG2E gene by SERMs.
Materials and Methods

Preparation of stable cell lines
Tetracycline-inducible U2OS-ER␣ cells were prepared and maintained as described previously (30) .
Plasmids, transfection, and luciferase assay
The NKG2E promoter was prepared by PCR using primers designed based on the human genome. The PCR product was cloned into the pGEM t-easy vector (Promega, Madison, WI) and sequenced. The promoter was then cloned upstream of the luciferase reporter gene. Deletions of the NKG2E promoter were prepared by using unique restriction sites (HindIII, PstI, and AccI). Point mutations in the NKG2E promoter were prepared with the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA). Transfections of the various vectors into wild-type U2OS cells were performed by electroporation (35) . Oligonucleotides were cloned upstream of Ϫ32 to ϩ45 thymidine kinase promoter-luciferase gene (TK-luc). Cells were assayed with a luciferase assay system according to the protocol of the manufacturer (Promega).
RNA extraction and quantitative real-time PCR
Total RNA was extracted and then treated with deoxyribonuclease using the Absolutely RNA miniprep kit (Stratagene). Reverse transcriptase reactions were performed using 1 g of total RNA as described previously (36) . Real-time PCR was performed with the Bio-Rad (Hercules, CA) iCycler using iQ SYBR Green Supermix. Mean Ϯ se was calculated using Prism curve-fitting program (version 3.03; GraphPad Software, San Diego, CA). Primers were designed using Oligo5.1 (National Biosciences, Inc., Plymouth, MN) and Amplify 1.2 (FaceWare) software and then blasted against all GenBank, Reference Sequence Nucleotides, European Molecular Biology Laboratory, DNA Data Bank of Japan, and Protein Data Bank sequences to verify that there was no cross-reaction with other genes. The sequences of the NKG2E primers used are as follows: forward, 5Ј-GCCAGCATTTTACCTTCCTCAT-3Ј; reverse, 5Ј-AACATGATGAAACCCCGTCTAA-3Ј.
Chromatin immunoprecipitation (ChIP)
After treatments, cells were cross-linked, washed, collected, and lysed as described previously (37, 38) . Fifty microliters of each sample were saved for total input. Immunoprecipitations were performed overnight at 4 C with anti-steroid receptor coactivator 1 (SRC-1) (1135), anti-heatshock factor 2 (HSF-2) (3E2) (Upstate, Charlottesville, VA), anti-ER␣ (HC-20), anti-c-jun (H-79), anti-CCAAT/enhancer-binding protein ␤ (C/EBP␤) (C-19) (Santa Cruz Biotechnology, Santa Cruz, CA), antiglucocorticoid receptor-interacting protein 1 (GRIP1) (ab9261), and amplified in breast cancer 1 (AIB1) (ab2782) (Abcam, Cambridge, MA). DNA fragments were purified (QIAquick PCR Purification kit; Qiagen, Valencia, CA) and PCR amplified. The NKG2E chip primers used were as follows: forward, 5Ј-AGCCACCCAAAGTCTCCTAT-3Ј; reverse, 5Ј-TTCAGTGGAGAGGTCAGGTT-3Ј. Real-time PCR using primers spanning sites far from the NKG2E response element and non-immune assays served as negative controls (data not shown).
Coimmunoprecipitation
After treatments, U2OS-ER␣ cells were washed and lysed [150 mm NaCl, 1% Triton X-100, and 50 mm Tris (pH 7.5)]. Fifty microliters of each sample were saved for total input. Immunoprecipitations were performed overnight at 4 C with anti-HSF-2, anti-C/EBP␤, or anti-c-jun antibodies mixed with protein-G agarose beads (Upstate). Beads were then washed and proteins eluted with SDS sample buffer containing dithiothreitol.
Immunoblotting
Proteins (15 g) were separated using 4 -12% gradient Bis-Tris gels (Invitrogen, Carlsbad, CA), transferred to polyvinylidene difluoride membranes, and detected with anti-HSF-2, anti-C/EBP␤, anti-c-jun, or anti-ER␣ antibodies in blocking buffer and anti-IgG conjugated with horseradish peroxidase (BD PharMingen, San Diego, CA). An ECL detection system (GE Healthcare Biosciences, Piscataway, NJ) was used to visualize the proteins.
RNA interference
RNA interference for C/EBP␤, c-jun, or nonspecific RNA was performed using SMARTpool small interfering RNA (siRNA) reagent (Dharmacon, Lafayette, CO). siRNA, 50 nm, was transfected into U2OS cells using oligofectamine (Invitrogen) according to the protocol of the manufacturer. For HSF-2, transient transfection of 3 g pSilencer 1.0-U6 (Ambion, Austin, TX) containing the hairpin forming oligonucleotides (5ЈCAGGCGAGTACAACAGCATTTCAAGAGAATGCTGTTGTAC-TCGCCTG3Ј and 5ЈCAGGCGAGTACAACAGCATTCTCTTGAAA-TGCTGTTGTACTCGCCTG3Ј) or an empty vector was used. At 72 h after transfections, cells were treated with E 2 for 12 h and collected for RNA and protein extraction.
EMSAs
32 P-labeled classical ERE or 32 P-labeled NKG2E (Ϫ1852 to Ϫ1687) regulatory element was incubated with or without purified ER␣ (Invitrogen) in buffer (30 mm HEPES, 120 mm KCl, 2 mm EDTA, 10 mm MgCl, 24% glycerol, and 2 g dIdC). Samples were then run on 6% polyacrylamide gel, which was dried and exposed to film.
Results
E 2 and SERMs activate the NKG2E gene
U2OS-ER␣ cells were treated with E 2 , tamoxifen, and raloxifene for increasing times, and then NKG2E mRNA was measured by quantitative real-time PCR. All three drugs activated the NKG2E gene by 6 h, and the maximal activation was observed by 24 h (Fig. 1A) . The E 2 -induced activation of the NKG2E gene was inhibited by tamoxifen and abolished by raloxifene (Fig. 1B ). These results demonstrate that tamoxifen and raloxifene act as a mixed agonist/antagonist at the NKG2E gene, because they activate the gene in the absence of E 2 and inhibit the gene in the presence of E 2 .
Multiple and distant elements are required for E 2 and SERM activation of the NKG2E gene
To study the mechanism whereby E 2 and SERMs regulate the NKG2E gene, we cloned a 3438 nucleotide fragment of the NKG2E promoter upstream of the luciferase reporter gene. The Ϫ3438 NKG2E promoter and several deletions ( Fig. 2A) were transiently cotransfected into U2OS cells with an expression vector for ER␣ and then treated with E 2 , tamoxifen, or raloxifene. Consistent with the mRNA expression data, all three drugs stimulated the Ϫ3438 and Ϫ1825 NKG2E promoters. E 2 produced a 12-fold activation of the NKG2E promoter, whereas tamoxifen and raloxifene activated the promoter by about 4-and 3-fold, respectively (Fig. 2B ). The magnitude of activation of the NKG2E promoter by the SERMs is similar to their activation at AP-1 (26) and Sp1 (25) elements. No activation by E 2 or SERMs occurred when the NKG2E promoter was deleted to Ϫ1686 (Fig. 2B ). These results demonstrate that the ER regulatory element is located between Ϫ1825 and Ϫ1686.
To further map the ER response element, the Ϫ1825 to Ϫ1686 NKG2E promoter fragment was cloned upstream of minimal TK-luc, and then deletions at the proximal and distal ends were prepared (Fig. 2C) . The constructs were transiently transfected into U2OS cells with the ER␣ expression vector. Similar to the native Ϫ3438 NKG2E promoter (Fig. 2B) , the Ϫ1825 to Ϫ1686 fragment was activated by both E 2 and SERMs (Fig. 2D) , Surprisingly, the activation was abolished by deletions at either end of the Ϫ1825 to Ϫ1686 region (Fig. 2D ). These findings demonstrate that E 2 and SERM activation of the NKG2E regulatory region requires multiple and distant elements.
The activation of the NKG2E promoter by E 2 and SERMs requires a transcriptional factor cluster and a unique variant ERE
The Ϫ1825 to Ϫ1686 region contains potential binding sites for multiple transcription factors, including AP-1, myeloid zinc finger (MZF-1), HSF-2, C/EBP␤, GATA, and octamerbinding transcription factor 1. This region also contains a variant ERE-like element (vERE) (Fig. 3A) . These elements were individually mutated and then tested in transient transfections for responses to E 2 and SERMs. The activation by E 2 was markedly inhibited by mutations in the AP-1, HSF-2, and C/EBP␤ elements (Fig. 3B) . These mutations also abolished tamoxifen and raloxifene activation of the promoter (Fig. 3B) . Mutations in the other transcription factor elements (Mzf-1, GATA, and octamer-binding transcription factor 1) did not have any effect on the activation by E 2 or SERMs (data not shown). The vERE (5Ј GGTAAccTGACC 3Ј) has a perfect distal half-site and a proximal half-site with one nucleotide difference compared with the classical ERE (5Ј GGTCAnnnT-GACC 3Ј). This site also differs from the classical ERE in that it contains two nucleotides, rather than the usual three, between the half-sites (Fig. 3C, top) . Mutations in the proximal or the distal vERE half-site sequence (Fig. 3C , middle and bottom, respectively) abolished the activation by E 2 and SERMs (Fig. 3D) , demonstrating that the complete vERE is required for activation.
To explore the functional significance of the vERE, we cloned the vERE upstream of TK-luc (Fig. 4A ) and transfected the construct into U2OS cells along with an ER␣ expression vector. We found that the vERE by itself was not activated by E 2 (Fig. 4B) or SERMs (data not shown). Similarly, the transcription factor cluster containing the AP-1, HSF-2, and C/EBP␤ elements upstream of TK-luc was not regulated by E 2 (Fig. 4B) or SERMs (data not shown), although it contains an AP-1 element. To determine whether the vERE is influenced by cluster proteins, an oligonucleotide containing the cluster elements positioned 24 bp proximal to the vERE was cloned upstream of TK-luc (Fig. 4A, bottom) . The activation by E 2 was restored when the cluster elements were positioned adjacent to the vERE (Fig. 4B) . However, the activation of cluster-vERE TK-Luc was about half of that observed with the wild-type vERE region. This finding likely results from the different number of nucleotides spaced between the cluster and vERE in the synthetic oligonucleotide (Fig. 4A, bottom) compared with the native sequence (Fig. 4A,  top) . These results demonstrate that the vERE is only active when cluster elements are present and define the ER␣ regulatory unit in the NKG2E gene, which consists of AP-1, HSF-2, and C/EBP␤ elements along with a vERE.
To investigate whether ER␣ binds directly to the vERE, we used an ER␣ mutant (HE82) with three mutations in the DNA binding domain that makes it unable to bind directly to an ERE (39). E 2 or SERMs failed to activate the transfected cluster-vERE TK-luc construct in the presence of HE82 (Fig. 4C) , suggesting that DNA binding is required for ER activation. To further explore this point, we performed EMSAs. We found that purified ER␣ did not bind to the native NKG2E regulatory region containing vERE but strongly bound to the classical ERE, which served as a positive control (Fig. 4D) . We also did not observe ER␣ binding with nuclear extracts prepared from E 2 -treated U2OS-ER␣ cells (data not shown). Altogether, these results show that the vERE is required for activation, although ER␣ does not bind directly to the vERE in EMSA. To reconcile these apparently conflicting data, we hypothesize that the cluster proteins form a complex with ER␣ that allows it to bind to the vERE. EMSA may not serve as an adequate method to detect ER␣ binding because it is done in conditions that might not allow the cluster proteins to form a complex with ER␣.
ER␣ interacts with AP-1, HSF-2, and C/EBP␤
The observation that mutations in the binding sites for the cluster proteins markedly inhibited E 2 and SERM activation of the NKG2E gene demonstrates the importance of these elements in NKG2E regulation. However, it is important to determine whether ER␣ interacts with the cluster proteins. U2OS-ER␣ cells were treated for increasing periods of time with E 2 , and cellular lysates were immunoprecipitated with antibodies to c-jun, HSF-2, or C/EBP␤. The immunoprecipitated proteins were run on a SDS-polyacrylamide gel, and Western blots were done with an ER␣ antibody. ER␣ interacted strongly with HSF-2 and C/EBP␤ after 1 h of E 2 treatment (Fig. 5A) . A decrease in the amount of HSF-2 and C/EBP␤ was observed at 2 and 3 h. This decrease might be attributable to the recruitment of ER, coactivators, and possibly other factors that make the antibodies less accessible for binding to HSF-2 and C/EBP␤. ER␣ also interacted with c-jun, but the binding was weaker at all time points. These results demonstrate that ER␣ interacts with a transcription factor complex containing c-jun, HSF-2, and C/EBP␤.
Kinetics of ER␣ and cluster protein assembly on the NKG2E promoter after E 2 treatment
Whereas the coimmunoprecipitation studies demonstrate that ER␣ interacts with the cluster proteins in intact cells, they do not show that these factors interact at the NKG2E promoter. To assess the occupancy of ER␣ and cluster proteins at the NKG2E promoter over time, we performed ki-
FIG. 2. Multiple and distant elements
are required to activate the NKG2E promoter by E 2 and SERMs. A, Different lengths of the NKG2E promoter located upstream of the luciferase reporter gene. B, Wild-type U2OS cells were transfected with NKG2E promoter-luciferase reporter constructs and an expression vector for ER␣. The cells were treated with 10 nM E 2 , 1 M tamoxifen, or 1 M raloxifene for 18 h, and luciferase activity was measured. C, The Ϫ1825 to Ϫ1686 region of the NKG2E promoter and deletion mutants of the proximal and distal ends were located upstream of the minimal TK promoter. D, U2OS cells were transfected with the Ϫ1825 to Ϫ1686 region of the NKG2E promoter or deletion mutant constructs along with an expression vector for ER␣. The cells were treated with 10 nM E 2 , 1 M tamoxifen, or 1 M raloxifene for 18 h, and luciferase activity was measured. Each data point is the average Ϯ SEM of triplicate determinations. *, P Ͻ 0.05, significant difference from control values.
netic ChIP assays. U2OS-ER␣ cells were treated with E 2 for 15, 30, 60, or 180 min before they were cross-linked with formaldehyde. ER␣ binding to the NKG2E promoter was first detected 15 min after E 2 treatment and steadily increased to reach maximal levels by 180 min (Fig. 5B) . The kinetics of HSF-2 binding to the NKG2E promoter was similar to ER␣. Significant C/EBP␤ binding only occurred at 180 min (Fig.  5B) . Similarly, recruitment of c-jun to the NKG2E promoter was only observed at 180-min treatment with E 2 , but the basal levels of c-jun bound to NKG2E gene were high (data not shown), suggesting that c-jun is already present at the promoter before E 2 treatment.
Silencing of c-jun, HSF-2, and C/EBP␤ inhibits E 2 -mediated activation of the NKG2E gene
To further explore a functional role for cluster proteins in ER␣ activation of the NKG2E gene, we used RNA interference to silence the cluster protein genes. After 3 d of gene silencing, we observed a significant reduction in c-jun, HSF-2, and C/EBP␤ protein levels (Fig. 5C ). The decline in protein levels was associated with a 40 -70% reduction in the activation of the NKG2E gene by E 2 (Fig. 5D-F 
The activation of the NKG2E promoter by E 2 and SERMs requires both activation function 1 (AF-1) and AF-2 domains of ER␣
ER contains two functional domains, AF-1 and AF-2, that mediate transcriptional activation in response to ligands (40) . AF-1 is located in the N-terminal A/B domains and is constitutively active (41) . The AF-1 is activated by antiestrogens, such as tamoxifen (26), which causes the recruitment of coactivators (42) (43) (44) . AF-2 is located in the ligand binding domain (LBD) and is activated by agonists that lead to the recruitment of coactivators (10) and is antagonized with SERMs by the recruitment of corepressors (9) . To explore the role of AF-1 and AF-2 in the activation of the NKG2E promoter, U2OS cells were transfected with the NKG2E promoter and an ER␣ mutant that lacks AF-1 (HE19) or two point mutations that impair AF-2 by preventing coactivator interaction (K362A and E542K) (45) . The activation of the NKG2E promoter by E 2 , tamoxifen, and raloxifene was abolished with HE19 (Fig. 6A) . A marked reduction in activation by E 2 and tamoxifen occurred with both AF-2 mutants, FIG. 3 . AP-1, HSF-2, C/EBP␤, and a vERE are required for E 2 and SERM activation of the NKG2E promoter. A, Mutations were made in the AP-1, HSF-2, and C/EBP␤ elements located within the Ϫ1825 to Ϫ1686 NKG2E promoter. B, U20S cells were cotransfected with the luciferase reporter constructs containing wild-type NKG2E or AP-1, HSF-2, or C/EBP␤ mutants and an ER␣ expression vector. The cells were treated with 10 nM E 2 , 1 M tamoxifen (Tamox), or 1 M raloxifene (Ralox) (top, middle, and bottom, respectively) for 18 h, and luciferase activity was measured. Each data point is the average Ϯ SEM of triplicate determinations. C, Mutations in both half-sites of the vERE located within the Ϫ1825 to Ϫ1686 NKG2E promoter. D, U20S cells were cotransfected with the luciferase reporter constructs containing wild-type vERE or mutations in the vERE. The cells were treated with 10 nM E 2 (E), 1 M tamoxifen (T), or 1 M raloxifene (R) for 18 h, and luciferase activity was measured. C, Control. Each data point is the average Ϯ SEM of triplicate determinations. *, P Ͻ 0.05, significant difference from control.
a, b , P Ͻ 0.05, significant difference between the indicated treatments.
whereas the effect of the AF-2 mutants was not as pronounced in the presence of raloxifene. These results indicate that E 2 and SERMs promote AF-1 and AF-2 cooperation to activate the NKG2E promoter.
Coactivator-specific recruitment by E 2 and SERMs
As mentioned above, we used the NKG2E gene as a model to better understand the mechanism whereby target genes are regulated by E 2 and SERMs. Therefore, we next sought to study the downstream factors involved in this regulation. It is well known that E 2 activates genes by recruiting p160/ SRC coactivators, SRC-1, SRC-2 (GRIP1), and SRC-3 (AIB1), (10, 46) to the AF-2 surface of ER (47) (48) (49) . However, the mechanisms involved in SERM activation of genes are poorly understood. After identifying the ER regulatory unit in the NKG2E gene, we examined whether the p160 coactivators play a role in the activation by SERMs. We performed ChIP with ER␣ or p160s antibodies. ER␣ was recruited to the NKG2E element after treatment with all three drugs (Fig. 6B) . E 2 and tamoxifen recruited GRIP1 (Fig. 6D) and AIB1 (Fig.  6E) to the NKG2E gene. Raloxifene recruited only AIB1 to the NKG2E gene (Fig. 6E) . None of the drugs recruited SRC-1 to the NKG2E gene (Fig. 6C) . It is unlikely that the lack of recruitment of SRC-1 is attributable to the differential expression of coactivators, because our microarray data show that SRC-1 and AIB1 mRNA levels are 7.5-fold and 2-fold higher than GRIP1 mRNA in U2OS-ER␣ cells (data not shown). Furthermore, we found that SRC-1 is recruited to other genes regulated by E 2 (data not shown), demonstrating that SRC-1 protein is expressed in the U2OS cells. These results demonstrate that level of recruitment of GRIP1 correlated with the activity of the ligands in functional assays and provide evidence that coactivators mediate the activation of the NKG2E gene by both E 2 and SERMs.
Discussion
We studied the NKG2E gene as a model to characterize a regulatory element derived from a native gene that is activated by both E 2 and SERMs in the presence of ER␣ (30) . The ER regulatory element was mapped to the Ϫ1.83 to Ϫ1.68 kb region of the NKG2E promoter. Surprisingly, our deletion and mutation studies showed that the NKG2E regulatory element is extremely complex and requires multiple and distant elements for regulation by E 2 and SERMs. The activation of the NKG2E promoter by E 2 and SERMs was inhibited by mutations in c-jun, HSF-2, and C/EBP␤ elements.
FIG. 4. The activation of the NKG2E
promoter requires a transcription factor cluster and a vERE. A, The native sequence (top) or a synthetic oligonucleotide (bottom) containing AP-1, HSF-2, and C/EBP␤ cluster elements and vERE in the ER regulatory element of the NKG2E gene. B, U20S cells were cotransfected with the vERE alone, cluster elements alone, or cluster elements and vERE and an expression vectors for ER␣. The cells were treated with 10 nM E 2 for 18 h, and luciferase activity was measured. C, U20S cells were cotransfected with the Ϫ3438 NKG2E construct and expression vectors for wild-type (WT) ER␣ or ER␣ HE82 mutant, which does not bind to an ERE. The cells were treated with 10 nM E 2 , 1 M tamoxifen (Tamox), or 1 M raloxifene (Ralox) for 18 h, and luciferase activity was measured. Each data point is the average Ϯ SEM of triplicate determinations. *, P Ͻ 0.05, significant difference from control values. D, The classical ERE or the NKG2E regulatory region containing the vERE were labeled with 32 P and incubated without (Ϫ) or with (ϩ) purified ER␣. EMSAs were done as described in Materials and Methods.
The NKG2E promoter does not contain a classical ERE but instead it has a vERE. This sequence includes a variant proximal half-site and a perfect distal half-site separated by only two nucleotides instead of three, which is characteristic of the classical EREs. Mutations in both half-sites of the vERE blocked the activation by E 2 and SERMs, demonstrating that both sites are required for full activation. This vERE was not detected in software designed to identify EREs. Furthermore, ER␣ did not bind to this element in gel shift assays, and the element was not activated by E 2 or SERMs upstream of the TK promoter. These findings demonstrate that the vERE is inactive on its own. In contrast, the vERE was activated by E 2 and SERMs in the presence of a transcription factor cluster containing c-jun, HSF-2, and C/EBP␤ elements positioned adjacent to the vERE. Surprisingly, the cluster by itself was not regulated upstream of TK, although it contains an AP-1 element.
Our ChIP analyses confirm that E 2 causes the assembly of a complex at the NKG2E regulatory element that consists of ER␣, c-jun, HSF-2, and C/EBP␤. The complex interactions between ER␣ and multiple transcription factors that are required for binding to the vERE could explain our inability to observe ER␣ binding in nuclear extracts prepared from U2OS-ER␣ cells treated with E 2 (data not shown). We propose that the role of the transcription factor cluster is to create a platform for ER binding and a functional ERE by stabilizing ER binding to the vERE. Without the cluster proteins, any binding of ER␣ to the vERE is probably too unstable for it to remain there long enough to recruit coactivators and other factors required for gene activation. It is known that single transcription factors, such as AP-1 (26) and Sp1 (18) , can interact with ER to alter the magnitude of regulation by estrogens and SERMs. More recently, it has been shown that the transcription factor forkhead box A1 can be essential for ER binding to DNA regulatory elements (50, 51) . Our study extends these findings by showing that ER␣ can interact with a cluster of transcription factors to regulate transcription at a vERE that by itself is incapable of binding ER␣ and therefore is nonfunctional. Unlike the typical EREs in known target genes, which ER␣ can bind to independent of other factors, our findings indicate that there are EREs induced by transcription factors. ER␣ can activate inducible EREs, such as the one in the NKG2E promoter, only when it is tethered to a transcription factor complex. The activation of the vERE most likely results from direct ER/DNA binding as demonstrated by the observation that the ERE binding mutant (HE82) was ineffective at activating the NKG2E promoter.
The observation that a vERE can be activated, although the half-sites are separated by only two nucleotides instead of the standard three, might significantly expand the number of EREs in the genome. Using bioinformatics to search the human genome, we found that there are 8199 genes that contain a putative ERE with a two nucleotide spacer. Of these genes, 3307 have expression data, of which 21 genes were regulated by estrogens by at least 1.5-fold change. Whereas it is unknown whether any of these genes are regulated by EREs containing a two nucleotide spacer, our data with the NKG2E regulatory element indicates that it conceivable that some of these genes are regulated by two spacer EREs.
We demonstrated that silencing of c-jun, HSF-2, and C/EBP␤ genes with siRNA resulted in a marked decline in the magnitude of induction of NKG2E mRNA after treatment with E 2 . These findings suggest that, in cells containing ER␣, the magnitude of activation of the NKG2E gene will be altered by the relative levels of c-jun, HSF-2, and C/EBP␤. In this model, only those tissues that express sufficient levels of c-jun, HSF-2, and C/EBP␤ would be expected to show an activation of the NKG2E gene by E 2 and SERMs with ER␣. Interestingly, a similar regulatory unit is also present in the NKG2D family member, which is differentially expressed in tissues. However, like NKG2E, NKG2D is also activated by E 2 and SERMs in the U2OS cells (data not shown). Our data along with the observations that HSF-2 (52) or C/EBP␤ (53) knock-out mice exhibit female subfertility or sterility also suggest that these transcription factors may have a more extensive role in the tissue-specific regulation of target genes by estrogens.
It is well established that SERMs exert antagonistic effects on gene expression by disrupting the AF-2 surface and recruiting corepressors, such as nuclear receptor corepressor, to ERs. In contrast, the mechanism underlying the agonist action of SERMs that leads to gene activation is poorly understood. Studies by Kushner et al. (19) have suggested that the activation at AP-1 elements by SERMs may involve the sequestration of corepressors, such as nuclear receptor corepressor or silencing mediator of retinoic acid and thyroid hormone receptors. By blocking corepressor recruitment to ER, the SERMs would allow activation function-1 (AF-1) activity in the A/B domain to operate more efficiently so as to activate the gene (49) . The role of the p160 coactivators in SERM gene activation is unclear. Structural analysis of the ER LBDs has shown that SERMs act as antagonists by blocking the movement of helix 12 to a position that creates a functional AF-2 surface. In fact, in the presence of SERMs, helix 12 actually occupies the coactivator binding site (49) . This prevents the binding of coactivators to the ER LBD required to activate gene transcription. These findings suggest that SERMs do not recruit p160s to activate genes. However, several studies suggest that coactivators may be involved in gene activation in response to SERMs. Coactivators can bind FIG. 6 . The activation of the NKG2E promoter by E 2 and SERMs requires both AF-1 and AF-2 domains of ER␣ and is mediated by p160 coactivators. A, U20S cells were cotransfected with the Ϫ3438 NKG2E construct and expression vectors for wild-type (WT) ER␣ or an ER␣ mutant, which lacks the AF-1 domain (HE19), or ER␣ mutants, which impair the AF-2 domain (K362A and E542K). The cells were treated with 10 nM E 2 , 1 M tamoxifen (Tamox), or 1 M raloxifene (Ralox) for 18 h, and luciferase activity was measured. B-E, U2OS-ER␣ cells were treated with 10 nM E 2 (E), 1 M tamoxifen (T), or 1 M raloxifene (R) for 3 h. C, Control. ChIP was performed using antibodies to ER␣, SRC-1, GRIP1, or AIB1 (B, C, D, and E, respectively). Immunoprecipitated chromatin fragments were PCR amplified and quantitated by real-time PCR using primers for the NKG2E promoter. Each data point is the average Ϯ SEM of three independent assays. *, P Ͻ 0.05, significant differences from control values.
to the A/B domain of ER in the presence of SERMs (42) (43) (44) , which could potentiate intrinsic AF-1 activity. Shang and Brown (54) reported that tamoxifen recruits the coactivator SRC-1 to genes activated in endometrial cells but not in MCF-7 breast cancer cells. Alternatively, it is conceivable that the AF-2 surface is not destroyed when ER is tethered to transcriptional factor complexes bound to NKG2E gene, which would allow some coactivator recruitment to the AF-2 surface even in the presence of SERMs. Another possible explanation is that the SERMs recruit coactivators to a unique surface of ER␣. Regardless of the precise location of the coactivator binding to ER␣, our studies clearly indicate that the agonist action of SERMs at the NKG2E gene is mediated by ER␣ recruitment of p160s coactivators. Our study demonstrates that the collaboration between multiple transcription factors and ER could be an important mechanism to elicit tissue-specific effects and determine the magnitude of gene activation by E 2 and SERMs. A greater understanding of the elements in native genes that mediate the regulation by E 2 and SERMs could provide the basis to develop safer SERMs that regulate only selective genes in target tissues.
